Brave New World of ATTR Cardiac Amyloidosis: Avoiding pitfalls in diagnosis and treatment

6:30 – 8:00 PM
Sunday, September 15, 2019
Pennsylvania Convention Center, 200 Level
Meeting Rooms 204 A/B
Philadelphia, PA

SYMPOSIUM AGENDA

6:30 PM Welcome and Introduction
Patient Perspective: The journey, the treatment, the costs, the outcome
• Martha Grogan & Mathew Maurer
6:40 PM Heightening Suspicion: Who is affected? • Brian Drachman
6:55 PM Initial Laboratory Evaluation • Ronald Witteles
7:10 PM Imaging: Focus on Nuclear Scintigraphy • Grace Lin
7:25 PM Emerging Treatment Options: How to choose and when to initiate • Mathew Maurer
7:40 PM Emerging Areas / Future Directions • Martha Grogan
7:50 PM Open Audience Q&A with Panel
8:00 PM Adjourn

LEARNING OBJECTIVES

Following this activity, participants will be able to:
• Identify signs, symptoms and features that should raise suspicion for a diagnosis of cardiac amyloidosis.
• Outline the methods available for testing for cardiac amyloidosis including limitations of specific tests.
• Discuss data from recent clinical trials outlining treatment options and potential patients who would benefit.
• Identify challenges and barriers to treatment, including disease severity, financial burden, and potential outcomes.
• Apply clinical algorithms to case studies.

ACCREDITATION

Physicians:
Accreditation statement: The Heart Failure Society of America is accredited by the Accreditation Council for Continuing Medical Education (ACCME) to provide continuing medical education for physicians. The Heart Failure Society of America designates this live activity for a maximum of 1.5 AMA PRA Category 1 Credits™. Physicians should claim only the credit commensurate with the extent of their participation in the activity.

Nurses:
This activity has been submitted to the Ohio Nurses Association for approval to award contact hours. The Ohio Nurses Association is accredited as an approver of continuing nursing education by the American Nurses Credentialing Center’s Commission on Accreditation (OBN-001-91). Please call HFSA at 301-312-8635 for more information about contact hours.

ELIGIBILITY

Registration for the 23rd Annual Scientific Meeting and an official name badge are required to attend this symposium.

Supported by independent medical education grants from Pfizer, and the Amyloidosis Research Consortium (including Akcea Therapeutics, Ionis Pharmaceuticals, and Eidos Therapeutics).

This satellite symposium is not part of the scientific program as planned by the Heart Failure Society of America Program Committee.